---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031572"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:30:32.297524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference

## Summary
- Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.
- QO mediated TUSC2 overexpression induced apoptosis in ALK+ cell lines and patient-derived organoids.
- Combination treatment showed reduced tumor regrowth 2 weeks after end of dosing vs single agents.
- Data support potential clinical trial of Reqorsa for ALK-EML4 positive NSCLC patients.

## SEC filing metadata
- accession: 0001437749-25-031572
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/0001437749-25-031572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/gnpx20251021d_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031572
- JSON: https://secwatch.observer/filing/0001437749-25-031572.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.